Boston Scientific Corporation achieved a narrow earnings beat in Q1 2022, with adjusted earnings per share of $0.39, surpassing the Zacks Consensus Estimate of $0.38. Despite total revenues rising to $3.03 billion and a year-over-year increase of 5.4%, net income fell significantly to $110 million. The company is banking on its Cardiovascular segment for continued growth and has updated its full-year guidance, predicting adjusted EPS between $1.74 and $1.79. Uncertainty remains as net income has notably dropped, reflecting challenges in maintaining profit margins.
“Boston Scientific · eked out · a narrow first-quarter beat · topped industry trends”
“Boston Scientific Corporation · posted adjusted earnings per share · 39 cents · first quarter of 2022”
“Boston Scientific Corporation · marked a rise from · year-ago figure · 5.4%”
“Boston Scientific Corporation · topped the Zacks Consensus Estimate by · a penny”
“Segmental Analysis · Boston Scientific reorganized its operational structure · core businesses · two reportable segments, MedSurg and Cardiovascular”
“Boston Scientific · generated maximum revenues from · Cardiovascular”
“Boston Scientific · updated full-year 2022 guidance”
“Stock in the medical-device company · has held its ground · this year · true”
“Boston Scientific Corp. · shares rose · 3.3% · premarket Wednesday”
“Boston Scientific Corp. · reported lower earnings · first quarter · than a year ago”
“Boston Scientific Corp. · beat · consensus estimates”
“Boston Scientific · reported quarterly earnings of · $0.39 per share · beating the Zacks Consensus Estimate of $0.38 per share”